安罗替尼联合化疗治疗非小细胞肺癌的效果及安全性

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect and safety of Anlotinib combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC).Methods A total of 57 patients with advanced NSCLC (third-line) diagnosed by the First Department of Oncology, People′s Hospital of Liaoning Province from July 2018 to January 2019 were selected as the research objects, and the patients were divided into observation group (29 cases) and control group (28 cases) by the random number table method.The control group was treated with conventional chemotherapy and symptomatic treatment, and the observation group was given oral Anlotinib Hydrochloride Capsules 12 mg/(times·d) for two weeks on the basis of conventional chemotherapy, with one week of withdrawal, three weeks as a treatment cycle, and the efficacy was evaluated at the sixth week.The clinical efficacy, survival indicators and incidence of adverse reactions were compared between the two groups.Results The disease control rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05).The progression-free survival of the observation group was longer than that of the control group, and the difference was statistically significant (P＜0.05).The overall survival in the observation group was longer than that in the control group, and the difference was statistically significant(P＜0.05).The main adverse reactions were abnormal liver function, anorexia, nausea and vomiting, leukopenia, abnormal renal function, thrombocytopenia, fatigue, diarrhea and bleeding.There was no statistically significant difference in the incidence rate of adverse reactions between the two groups (P ＞0.05).Conclusion Anrotinib combined with chemotherapy for the treatment of NSCLC can effectively control the development of the disease, prolong the survival time of patients, and has good safety.

Key words： Anlotinib Non-small cell lung cancer Treatment effect Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I8/81

[18]	庄荣源，王志明，郭曦，等.安罗替尼联合化疗治疗晚期软组织肉瘤的近期疗效及安全性分析[J].中国临床医学，2019，26（3）：378-381.
[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]	Chen Z，Zhong B，Lun X，et al.Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC：A Meta-Analysis[J].Medicine （Baltimore），2015，94（24）：e975.
[3]	雷泽民，余宗阳.非小细胞肺癌T细胞PD-1 免疫靶向治疗研究现状与展望[J].中国肿瘤，2015，24（5）：398-402.
[4]	石远凯，孙燕，于金明，等.中国肺癌脑转移诊治专家共识（2017年版）[J].中国肺癌杂志，2017，20（1）：1-12.
[5]	苏雨栋，孟昭婷，徐晓燕，等.安罗替尼治疗KR AS 突变型晚期肺腺癌1例[J].中国肺癌杂志，2018，21（5）：428-430.
[6]	Sun Y，Niu W，Du F，et al.Safety，pharmacokinetics，and antitumor properties of anlotinib，an oral multi-target tyrosine kinase inhibitor，in patients with advanced refractory solid tumors[J].J Hematol Oncol，2016，9（1）：105.
[7]	罗详冲.安罗替尼治疗肺癌的临床研究进展[J].中国肿瘤生物治疗杂志，2019，26（6）：710-714.
[8]	Han B，Li K，Wang Q，et al.Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer：The ALTER 0303 Phase 3 Randomized Clinical Trial[J].JAMA Oncol，2018，4（11）：1569-1575.
[9]	He C，Wu T，Hao Y.Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway[J].Biochem Biophys Res Commun，2018，503（4）：3093-3099.
[10]	Sun Y，Du F，Gao M，et al.Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J].Thyroid，2018，28（11）：1455-1461.
[11]	Ruan X，Shi X，Dong Q，et al.Antitumor effects of anlotinib in thyroid cancer[J].Endocr Relat Cancer，2019，26（1）：153-164.
[12]	Chi Y，Fang Z，Hong X，et al.Safety and Efficacy of Anlotinib，a Multikinase Angiogenesis Inhibitor，in Patients with Refractory Metastatic Soft-Tissue Sarcoma[J].Clin Cancer Res，2018，24（21）：5233-5238.
[13]	林建光，许天文，傅德强，等.白蛋白结合型紫杉醇一线治疗40例晚期肺鳞癌的观察[J].中国肿瘤临床，2018，45（8）：394-397.
[14]	辛涛，金发光，刘伟，等.盐酸安罗替尼胶囊治疗晚期非小细胞肺癌的临床研究[J].中华肺部疾病杂志（电子版），2018，11（5）：559-562.
[16]	李莲港，姜军.安罗替尼在肺癌治疗中的研究进展[J].中国当代医药，2020，27（2）：12-14.
[17]	赵秧，陈倩，康马飞，等.安罗替尼治疗晚期胰腺癌疗效观察[J].中国现代医生，2020，58（1）：121-123，126.
[15]	Costa DB，Shaw AT，Ou SH，et al.Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases[J].J Clin Oncol，2015，33（17）：1881-1888.